News about Drug Discovery & Development

AstraZeneca's Calquence-Venetoclax Regimen Approved in US as First All-Oral Fixed-Duration Therapy for CLL

FDA clears 14-month, chemotherapy-free combination for first-line treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma, backed by positive Phase III AMPLIFY trial data.

Drug Discovery & Development | 23/02/2026 | By News Bureau |  244

Chugai Launches Elevidys Gene Therapy for Duchenne Muscular Dystrophy in Japan

Elevidys receives conditional approval and NHI listing for ambulatory DMD patients aged three to under eight years; launch backed by Phase III EMBARK study and strengthened safety measures.

Drug Discovery & Development | 23/02/2026 | By News Bureau |  307

FDA Approves Vanda Pharmaceuticals' BYSANTI as First-Line Therapy for Bipolar I Disorder and Schizophrenia

BYSANTI (milsaperidone), a new atypical antipsychotic from Vanda Pharmaceuticals, gains FDA approval for acute manic or mixed episodes in bipolar I disorder and schizophrenia in adults, with US launch planned for Q3 2026.

Drug Discovery & Development | 21/02/2026 | By News Bureau |  331

Shield Therapeutics' ACCRUFeR Becomes First FDA-Approved Oral Iron Therapy for Children Aged 10 and Above

Shield Therapeutics secures expanded U.S. Food and Drug Administration approval for ACCRUFeR (ferric maltol) to treat iron deficiency in pediatric patients aged 10 and above, addressing a major unmet need.

Drug Discovery & Development | 20/02/2026 | By News Bureau |  185

GRAIL Reports Topline Results from NHS-Galleri Trial of Multi-Cancer Early Detection Test

Results from the NHS-Galleri trial show that annual multi-cancer screening with the Galleri test reduced Stage IV diagnoses and significantly increased early cancer detection across England’s NHS population.

Drug Discovery & Development | 20/02/2026 | By News Bureau |  372

Merck and Mayo Clinic Partner to Accelerate AI-Driven Drug Discovery and Development

Merck, known as MSD outside the United States and Canada, has entered into a strategic research and development agreement with Mayo Clinic, one of the world’s leading hospital systems, to advance the use of artificial intelligence (AI), advanced analytics and multimodal clinical data in drug discovery and development.

Drug Discovery & Development | 20/02/2026 | By Darshana |  140

GSK Reports Real-World Data Showing Strong Effectiveness of RSV Vaccine in Older Adults

New US and Denmark studies presented at ReSViNET 2026 show GSK’s RSV vaccine is associated with reduced hospitalisations and lower risk of severe cardiovascular and respiratory complications in adults aged 60 and above.

Drug Discovery & Development | 19/02/2026 | By News Bureau |  192

Global Molecular Diagnostics Market to Reach USD 38.01 Billion by 2034, Driven by Precision Medicine Demand

The global molecular diagnostics market is projected to reach USD 38.01 billion by 2034, according to a new report by Polaris Market Research. The study provides an in-depth assessment of market size, share, emerging trends, and growth forecasts from 2025 to 2034, highlighting the sector’s expanding role in modern healthcare.

Drug Discovery & Development | 19/02/2026 | By Darshana |  132

Diakonos Oncology Phase II Glioblastoma Trial Cleared to Continue After DSMB Safety Review

Independent safety review clears Diakonos Oncology’s Phase II DOC1021 glioblastoma trial to proceed, with no safety concerns identified to date.

Drug Discovery & Development | 18/02/2026 | By News Bureau |  209

GSK Wins EU Approval for Exdensur in Severe Asthma and CRSwNP

European Commission clears twice-yearly depemokimab for type 2 inflammation-driven severe asthma and chronic rhinosinusitis with nasal polyps, backed by positive Phase III SWIFT and ANCHOR data.

Drug Discovery & Development | 18/02/2026 | By News Bureau |  154